News

By Sara Gilgore – Staff Reporter, Washington Business Journal – Johnson & Johnson Innovation’s D.C. incubator is preparing to leave Children’s National Hospital’s Research and Innovation Campus at Walter Reed.

J&J’s innovation arm informed the pediatric health system that it intends to “begin transitioning site operations and management for select JLabs locations back to site owners in 2026,” Dr. Nathan Kuppermann, Children’s National’s chief academic officer, wrote Tuesday in an internal memo to staff, obtained by the Washington Business Journal.

The JLabs incubator will begin winding down its operations at that site ahead of a planned departure in January 2026, according to the email. Kuppermann said the change “does not alter” the system’s vision or long-term goals and, rather, “opens the door to new possibilities for growth and innovation” at the campus.

Richmond, VA, July 22, 2025 (GLOBE NEWSWIRE) — Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), today announced the successful close of its Series C financing round at an increased valuation from previous funding. The $37 million raise supports the Company’s mission of helping brilliant minds bring medicines to life through advanced development and manufacturing in America. The growing Company’s Series C round was led by Align Private Capital LLC, a woman-owned investment firm which manages private family office direct investment vehicles, and was supported by additional new and follow-on investors.

7/17/2025 – Gwendolyn Wu – Even before HSBC’s report, there were signs of a biotech funding slowdown.

Research the investment bank Jefferies published in May and again in June found a substantial pullback in financing in public companies. Private rounds tracked by BioPharma Dive have gotten larger, but are fewer in number, too, as venture firms appear to be favoring surer bets. Initial public offerings have largely been on pause since the middle of February.

HSBC’s findings detail the fallout for drug startups more specifically. A combination of worries over pharmaceutical tariffs, research funding cuts and leadership changes at public health agencies drove a slump that led to startups’ worst quarter in terms of seed or Series A funding rounds since 2023, according to Jonathan Norris, a managing director at HSBC Innovation Banking.

COLUMBIA, Md., (July 21, 2025) — TEDCO, Maryland’s economic engine for technology companies, announced a recent Venture Funds investment for nearly $350,00 in Zero Point Five Therapeutics. TEDCO’s evergreen Venture Funds are committed to investing in and advancing early-stage technology and life sciences companies across Maryland. These funds provide startups with access to a seasoned team dedicated to supporting their entrepreneurial growth and success.

Planning is well underway for BioHealth Capital Region Week 2025, and hundreds of attendees have already registered for the Forum taking place September 23–25 at US Pharmacopeia in Rockville, Maryland. Now in its 11th year, this free, three-day event brings together the people shaping the future of biohealth, including industry leaders, entrepreneurs, investors, government officials, and academic researchers, for insight, collaboration, and deal-making.

With this year’s theme, “Where Human and Artificial Intelligence Converge in the BioHealth Industry,” the program offers a timely look at how new technologies are transforming the entire innovation pipeline—from early-stage research through commercialization and patient impact.

The week opens with the BioHealth Capital Region Forum on September 23 and 24. This two-day event will feature keynote speakers, panels, and networking focused on industry trends, workforce strategies, and the impact of AI on research, development, and clinical decision-making. Whether you’re looking for policy updates, partnering opportunities, or inspiration, the Forum delivers valuable insight and access. Register today at https://bit.ly/BHCRWeek2025.

ROCKVILLE, Md., July 17, 2025 (GLOBE NEWSWIRE) — I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that it entered into a definitive agreement to acquire 100% ownership of Bridge Health Biotech Co., Ltd. (Bridge Health). The transaction provides I-Mab with the rights to bispecific and multi-specific applications (including bispecific and multi-specific antibodies and antibody drug conjugates (ADCs)), based on the Claudin 18.2 (CLDN18.2) parental antibody used in the Company’s CLDN18.2 x 4-1BB bispecific antibody, givastomig.

WASHINGTON, July 15, 2025 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (the “Company” or “60 Degrees”) (Nasdaq: SXTP; SXTPW), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the pricing of a public offering of 2,631,578 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) and accompanying Series A-1 warrants to purchase up to 2,631,578 shares of common stock and short-term Series A-2 warrants to purchase up to 2,631,578 shares of common stock, at a combined offering price of $1.90 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants.

BETHESDA, Md., July 15, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase common stock in an underwritten public offering. Gain expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and/or the warrants offered in the offering. All of the securities are being offered by the Company.

BETHESDA, Md.–(BUSINESS WIRE)–Today, the Cystic Fibrosis Foundation announced an additional investment of up to $24 million in Prime Medicine to continue the development of a gene editing therapy for people with cystic fibrosis (CF).

Prime Medicine uses a gene editing technology called prime editing — a technology that enables a wide range of modifications to the DNA with a high degree of precision. The company — founded by Drs. David Liu and Andrew Anzalone, who pioneered the development of this unique editing technology — is investigating whether prime editing could treat several diseases, including CF.